Abstract:Lassa virus (LASV) is responsible for 100,000-300,000 zoonotic infections annually and poses a threat to public health. Development of antibody-based therapeutics or vaccines has been challenging because neutralizing antibodies – even among Lassa hemorrhagic fever survivors – are generally of low titer, and the target of neutralizing antibodies, the trimeric glycoprotein complex (GPC), a type 1-fusion machine with GP1 and GP2 subunits, has been difficult to produce. Here, we use structure-based design to obtain a soluble LASV GPC by engineering an inter-protomer disulfide (R207GCGP1-L326CGP2) and appending the T4-fibritin trimerization domain. We verified the antigenicity of this prefusion-stabilized LASV GPC against a panel of human antibodies and used electron microscopy (EM) to confirm its trimeric association. We panned the prefusion-stabilized LASV GPC against single domain ‘nanobody’ libraries and identified one of camel origin, which we named D5, which bound GPC with 27 nM affinity and neutralized the Josiah strain of LASV with an IC50 of 12 µg/ml when formatted into a bivalent IgG2a context. The cryo-EM structure of a ternary complex of the D5 nanobody, the antigen-binding fragment of human antibody 8.11G, and LASV GPC revealed D5 to recognize a site-of-vulnerability at the trimer apex. The recognized site appeared to be specific to GPC lacking cleavage of between GP1 and GP2 subunits. Collectively, our findings suggest that GPC-cleavage intermediates may be targets for LASV neutralization and define an apex-situated site of vulnerability for vaccine development. Significance Lassa virus (LASV) infection is expanding outside its traditionally endemic areas in West Africa, posing a biothreat to the world. LASV-neutralizing antibodies, moreover, have proven difficult to elicit. To gain insight into requirements for antibody-mediated neutralization of LASV, we developed a prefusion-stabilized LASV glycoprotein trimer (GPC), panned it against phage libraries comprised single-domain antibodies or nanobodies from shark and camel, and identified one, D5, which – when placed into bivalent IgG2a context – could neutralize LASV. Cryo-EM analysis revealed D5 to recognize a cleavage-dependent site-of-vulnerability at the trimer apex. We propose this apex-situated site to be an attractive target for LASV vaccine and therapeutic development.

Machine Learning Reveals Key Glycoprotein Mutations and Rapidly Assigns Lassa Virus Lineages

Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex

Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates

Genome-wide association study identifies human genetic variants associated with fatal outcome from Lassa fever

Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates

Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability

Unraveling factors responsible for pathogenic differences in Lassa virus strains

Identification of Residues in Lassa Virus Glycoprotein Subunit 2 That Are Critical for Protein Function

Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability

Time-dependent failure of amorphous poly-D,L-lactide: influence of molecular weight.

Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak

Structure of the Lassa Virus Glycan Shield Provides a Model for Immunological Resistance.

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs

Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments

The long-term burden of severe sepsis and septic shock: Sepsis recidivism and organ dysfunction

Spatio-temporal spread and evolution of Lassa virus in West Africa

Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies

The Importance of Lassa Fever and Its Disease Management in West Africa

Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch

Comparing the efficacy of FeLV vaccines: comment on: Stuke, K. et al. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge. Vaccine 2014;32(22):2599-603.